You are here

Home » Library » Topic Index » Antiretroviral Therapy » Initiating Treatment

Initiating Treatment

Active Resources: 8

Antiretroviral Guidelines

Online Training

Toolkits

Image Library

Clinical Reference Tools

Articles: 5

  • FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine

    Susa Coffey's picture

    April 19, 2019

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients. The approval specifies that DTG/3TC is...

  • Immediate ART Initiation: Guide for Clinicians

    Susa Coffey's picture

    February 14, 2019

    Immediate antiretroviral therapy (ART) refers to starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first clinic visit (and even on the same day the HIV diagnosis is made). This strategy also is known as "rapid ART," "same-day ART," and "treatment...

  • Doravirine in Initial Therapy: DRIVE-AHEAD Study

    Susa Coffey's picture

    October 3, 2017

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the...

  • Bictegravir in Initial Therapy

    Susa Coffey's picture

    September 28, 2017

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...

  • START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV

    Jennifer Cocohoba's picture

    October 1, 2015

    The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...